SELECT PUBLICATIONS

Chlebowski RT et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20(15):3328-43. Abstract

Cuzick J et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360(9336):817-24. Abstract

Cuzick J et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361(9354):296-300. Abstract

Fisher B et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl CancerInst 1998;90(18):1371-88. Abstract

Freedman AN et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl CancerInst 2003;95(7):526-32. Abstract

Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19(3):881-94. Abstract

Goss PE, Strasser-Weippl K. Aromatase inhibitors for chemoprevention. Best Pract Res Clin Endocrinol Metab 2004;18(1):113-30. Abstract.

Peshkin BN et al. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003;21(23):4322-8. Abstract

Smith RE, Good BC. Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr Relat Cancer 2003;10(3):347-57. Abstract